

Wearable Injectors Market by Type(On-body, Off-body), Technology (Spring, Motor Drive, Expanding Battery, Rotary Pump), Indications (Diabetes, Immuno- Oncology, Cardiovascular, Chronic Pain), End Users (Hospital & Clinic, Homecare) - Global Forecast to 2029

Market Report | 2024-02-09 | 237 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global wearable injectors market is projected to reach USD 15.1 billion by 2029 from USD 8.4 billion in 2023, at a CAGR of 10.3% during the forecast period. Precise, user-friendly design, efficient delivery of large molecules, favorable reimbursements, numerous applications in drug delivery, the seamless subcutaneous flow of drugs, rise in the adoption of chronic diseases, and increased adoption of convenient drug delivery devices. The increased cost of wearable injectors and the high use of injection pens are challenges to growth in wearable injectors.

"On body wearable injectors segment accounted for the largest share and is expected to grow at the highest rate during the forecast period."

On-body injectors, often equipped with the wisdom of smart features, offer a window into medication administration and adherence. Missed doses become a distant memory, usage patterns focus, and timely reminders keep the treatment waltz in rhythm, leading to improved health and fewer complications. Miniaturization promises a lighter, more discreet, while advancements in data security and accessibility will break down the barriers to entry. As manufacturers focus on affordability and diverse needs, on-body injectors have the potential to democratize healthcare, empowering millions to take control of their health with newfound confidence and independence.

"The rotary pump segment accounted for the highest growth during the forecast period."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Unlike spring-based or motor-driven systems, rotary pumps deliver unwavering accuracy in medication dosage. Their fluid mechanics ensure consistent flow, minimizing the risk of errors and maximizing therapeutic effectiveness, particularly for medications requiring precise micro-doses. will drive the growth of the wearable injectors market. Rotary pumps achieve this magic with their smooth, low-pressure delivery, reducing pain and discomfort for patients, especially those with needle anxieties. Plus, their compact design translates to discreet and convenient use, seamlessly integrating into daily routines.

"Immuno oncology segment accounted for the second largest share of the market."

Wearable injectors, with their user-friendly designs and intuitive interfaces, become an extension of the patient's therapeutic rhythm, reducing the dissonance of missed doses and ensuring sustained efficacy. This harmonization potentially amplifies treatment outcomes, particularly in immuno-oncology where precise administration is crucial. However, the score of healing can be laced with discomfort, a disruptive counterpoint for patients already battling their disease. Here, wearable injectors offer a gentle counter-melody. Their low-pressure delivery minimizes the cacophonous notes of injection anxiety, allowing patients to focus on the therapeutic crescendo within. This newfound autonomy, the ability to self-administer at their own tempo, liberates patients from the clinical constraints, transforming them into soloists in their own health journey.

"Hospitals and clinics are the end-user segment held the largest market share in the wearable injectors market."

Wearable injectors are quietly claiming center stage, emerging as discreet allies in chronic disease management. These compact companions, adhering directly to the body, orchestrate medication delivery with precision, often minimizing the overall number of injections and granting patients an unprecedented level of control over their treatment. The allure of these miniature maestros lies in their ability to transcend the confines of hospital walls. Imagine ditching the sterile atmosphere and lengthy waits for home-based medication administration. Wearable injectors liberate patients from the shackles of institutional routines, reducing unnecessary clinic visits and the associated risk of hospital-acquired infections. This shift not only empowers individuals but also aligns with the digital health revolution, paving the way for seamless connectivity and remote monitoring of chronic conditions. "North America to Witness Significant Growth From 2023 to 2029."

Wearable injectors market has been segmented into five major regional segments: North America, Europe, Asia Pacific, Latin America and Middle East and Africa and GCC. In 2022, the Asia Pacific region is anticipated to exhibit the highest compound annual growth rate (CAGR) during the forecast period. However, the North American market held the largest market share of the global market. North America stands as the frontrunner in the wearable injectors market, commanding the largest market share throughout the forecast period. North America boasts a well-developed healthcare infrastructure, fertile ground for nurturing research and development of cutting-edge technologies. Leading manufacturers find a welcoming stage here, their expertise fueling a thriving ecosystem of collaboration with universities, research labs, and other industry players. This collaborative spirit results in a constant crescendo of innovation, propelling the wearable injector market forward.

Breakdown of supply-side primary interviews: - By Company Type: Tier 1 - 35%, Tier 2 - 50%, and Tier 3 - 15% - By Designation: C-level - 35%, Director-level - 40%, and Others - 25% - By Region: North America - 30%, Europe - 25%, APAC - 20%, Latin America - 15%, Middle East & Africa - 7% GCC- 3%

Some of the prominent players in the wearable injectors market are Amgen Inc. (US), Medtronic PLC (Europe), Insulet Corporation (US), Tandem Diabetes Care, Inc. (US), United Therapeutics Corporation (US), Abbvie Inc. (US), Gerresheimer AG (Germany), Becton Dickinson and Company (US), West Pharmaceutical Services Inc. (US), Ypsomed AG (Switzerland), Enable Injections (US), Subcuject APS (Denmark), CeQur Simplicity (Switzerland), Mannkind Corporation (US), Sonceboz (Switzerland), CC Bio (Japan), Elcam Drug Delivery Devices (Israel), Stevanato Group (Italy), Debiotech SA (Switzerland), Bexson Biomedical (US), Nemera (France), LTS Lohmann Therapie Systeme AG (Germany), Kymanox Corporation (US), Novo Engineering (US), and Eoflow (South Korea).

Research Coverage

This report studies the wearable injectors market based on type, technology, indication, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

- Analysis of key drivers (increasing prevalence of diabetes, technological advancements in wearable injectors devices, advent of artificial intelligence in wearable injectors, favorable reimbursements scenario in major markets, low -complexity, easy- to- use wearable injection platform), restraints (high cost of wearable injectors, oral insulin as an alternative drug delivery method), opportunities (increasing research and development activities and strategic partnerships and increased adoption of on-body wearable injectors), and challenges (needlestick injuries and misuse of injection pens) influencing the growth of wearable injectors market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in wearable injectors market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of respiratory diagnostics across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in wearable injectors market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the wearable injectors market.

Table of Contents:

1□INTRODUCTION□32

1.1□STUDY OBJECTIVES□32

1.2□MARKET DEFINITION□33

1.3□INCLUSIONS & EXCLUSIONS□34

1.4□MARKET SCOPE□34

1.4.1□MARKETS COVERED□34

1.4.2□REGIONS COVERED□35

1.4.3□YEARS CONSIDERED□35

1.4.4□CURRENCY CONSIDERED□35

TABLE 1□EXCHANGE RATES UTILIZED FOR CONVERSION TO USD□36

1.5□STAKEHOLDERS□36

1.6□SUMMARY OF CHANGES□36

1.6.1□RECESSION IMPACT: WEARABLE INJECTORS MARKET□37

2□RESEARCH METHODOLOGY□38

2.1□RESEARCH DATA□38

FIGURE 1□RESEARCH DESIGN□38

2.1.1□SECONDARY DATA□38

2.1.1.1□Key data from secondary sources□40

2.1.2□PRIMARY DATA□40

FIGURE 2□PRIMARY SOURCES□40

2.1.2.1□Key data from primary sources□41

2.1.2.2□Key industry insights□42

2.1.2.3	Breakdown of primary interviews	42
FIGURE 3	BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION	42
FIGURE 4	BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION	43
FIGURE 5	BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS	43
2.2	MARKET SIZE ESTIMATION	43
FIGURE 6	SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS	44
FIGURE 7	REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC.	44
FIGURE 8	SUPPLY-SIDE ANALYSIS OF TOP COMPANIES: WEARABLE INJECTORS MARKET (2022)	45
FIGURE 9	CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES, 2023-2029	46
FIGURE 10	CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS	47
FIGURE 11	TOP-DOWN APPROACH	47
2.3	DATA TRIANGULATION	48
FIGURE 12	MARKET DATA TRIANGULATION	48
2.4	MARKET SHARE ESTIMATION	49
2.5	STUDY ASSUMPTIONS	49
2.6	RESEARCH LIMITATIONS	49
2.6.1	METHODOLOGY-RELATED LIMITATIONS	49
2.6.2	SCOPE-RELATED LIMITATIONS	49
2.7	RISK ASSESSMENT	50
TABLE 2	RISK ASSESSMENT: WEARABLE INJECTORS MARKET	50
2.8	IMPACT OF ECONOMIC RECESSION ON WEARABLE INJECTORS MARKET	50
3	EXECUTIVE SUMMARY	51
FIGURE 13	WEARABLE INJECTORS MARKET, BY TYPE, 2023 VS. 2029 (USD MILLION)	51
FIGURE 14	WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2023 VS. 2029 (USD MILLION)	52
FIGURE 15	WEARABLE INJECTORS MARKET, BY INDICATION, 2023 VS. 2029 (USD MILLION)	53
FIGURE 16	WEARABLE INJECTORS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)	54
FIGURE 17	REGIONAL SNAPSHOT OF WEARABLE INJECTORS MARKET	55
4	PREMIUM INSIGHTS	56
4.1	WEARABLE INJECTORS MARKET OVERVIEW	56
FIGURE 18	INCREASING PREVALENCE OF CHRONIC DISEASES AND RISING HEALTHCARE EXPENDITURE TO DRIVE MARKET	56
4.2	ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER & REGION, 2022	57
FIGURE 19	CHINA AND HOSPITALS AND CLINICS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022	57
4.3	GEOGRAPHIC GROWTH OPPORTUNITIES: WEARABLE INJECTORS MARKET	58
FIGURE 20	US TO REGISTER HIGHEST MARKET GROWTH RATE DURING FORECAST PERIOD	58
4.4	WEARABLE INJECTORS MARKET: DEVELOPED VS. EMERGING ECONOMIES	59
FIGURE 21	EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING STUDY PERIOD	59
5	MARKET OVERVIEW	60
5.1	INTRODUCTION	60
5.2	MARKET DYNAMICS	60
FIGURE 22	DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES: WEARABLE INJECTORS MARKET	60
5.2.1	DRIVERS	61
5.2.1.1	Increasing prevalence of diabetes among geriatric population	61
TABLE 3	TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20-79 YEARS), 2021 VS. 2045	61
5.2.1.2	Technological advancements in wearable injectors	61
5.2.1.3	Use of artificial intelligence in diabetes care devices	62
5.2.1.4	Favorable reimbursement scenario	63
5.2.1.5	Development of low-complexity and easy-to-use wearable injectors	63

5.2.2	RESTRAINTS	64
5.2.2.1	High cost of wearable injectors and lack of reimbursement plans in emerging economies	64
5.2.2.2	Increased focus on alternative drug delivery methods	64
5.2.3	OPPORTUNITIES	65
5.2.3.1	Increased number of R&D activities and strategic partnerships	65
5.2.3.2	Growing adoption of on-body wearable injectors	65
5.2.4	CHALLENGES	66
5.2.4.1	Lack of training and education for using new delivery devices	66
5.3	INDUSTRY TRENDS	66
5.3.1	INCREASING ADOPTION OF WEARABLE DRUG DELIVERY SYSTEMS	66
5.3.2	RISING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS	67
TABLE 4	RECENT COLLABORATIONS IN WEARABLE INJECTORS MARKET	67
5.3.3	INTEGRATION OF LIQUID SILICONE RUBBER TECHNOLOGY IN WEARABLE HEALTH MONITORING AND DRUG DELIVERY DEVICES	67
5.4	TECHNOLOGY ANALYSIS	68
5.5	SUPPLY CHAIN ANALYSIS	69
FIGURE 23	SUPPLY CHAIN ANALYSIS: WEARABLE INJECTORS MARKET	69
5.6	VALUE CHAIN ANALYSIS	70
FIGURE 24	VALUE CHAIN ANALYSIS: WEARABLE INJECTORS MARKET	71
5.7	ECOSYSTEM MARKET/MAP	71
FIGURE 25	ECOSYSTEM MARKET/MAP: WEARABLE INJECTORS MARKET	71
5.8	TRADE ANALYSIS	72
TABLE 5	IMPORT AND EXPORT DATA FOR WEARABLE INJECTORS, BY COUNTRY	72
5.9	PORTER'S FIVE FORCES ANALYSIS	72
TABLE 6	PORTER'S FIVE FORCES ANALYSIS: WEARABLE INJECTORS MARKET	72
5.9.1	INTENSITY OF COMPETITIVE RIVALRY	73
5.9.2	BARGAINING POWER OF SUPPLIERS	73
5.9.3	BARGAINING POWER OF BUYERS	73
5.9.4	THREAT OF SUBSTITUTES	73
5.9.5	THREAT OF NEW ENTRANTS	73
5.10	TARIFF & REGULATORY LANDSCAPE	74
5.10.1	REGULATORY ANALYSIS	74
5.10.1.1	North America	74
5.10.1.1.1	US	74
5.10.1.1.2	Canada	74
5.10.1.2	Europe	74
5.10.1.3	Asia Pacific	74
5.10.1.3.1	China	74
5.10.1.3.2	Japan	75
5.10.1.3.3	India	75
5.10.1.4	Latin America	75
5.10.1.4.1	Brazil	75
5.10.1.4.2	Mexico	75
5.10.1.5	Middle East	76
5.10.1.6	Africa	76
5.10.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	76
TABLE 7	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 8	EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	76
TABLE 9	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
TABLE 10	LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
TABLE 11	MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	77
5.11	PATENT ANALYSIS	78
5.11.1	PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS	78
FIGURE 26	PATENT PUBLICATION TRENDS (JANUARY 2018-MAY 2023)	78
5.11.2	TOP APPLICANTS (COMPANIES) FOR WEARABLE INJECTOR PATENTS	79
FIGURE 27	TOP APPLICANT COMPANIES FOR WEARABLE INJECTOR PATENTS, 2018-2023	79
5.11.3	JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR WEARABLE INJECTOR PATENTS	80
FIGURE 28	JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR WEARABLE INJECTOR PATENTS, 2018-2023	80
5.12	PRICING ANALYSIS	80
5.12.1	AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYER	80
TABLE 12	AVERAGE SELLING PRICE OF WEARABLE INJECTORS, BY KEY PLAYERS, 2022	80
5.13	KEY CONFERENCES & EVENTS, 2023-2024	81
TABLE 13	DETAILED LIST OF KEY CONFERENCES & EVENTS IN WEARABLE INJECTORS MARKET, 2023-2024	81
5.14	KEY STAKEHOLDERS & BUYING CRITERIA	82
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	82
FIGURE 29	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES	82
TABLE 14	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE DISEASES (%)	82
5.14.2	BUYING CRITERIA	82
FIGURE 30	KEY BUYING CRITERIA FOR TOP THREE DISEASES	82
TABLE 15	KEY BUYING CRITERIA FOR TOP THREE DISEASES	83
5.15	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	83
5.16	UNMET NEEDS	83
5.17	ADJACENT MARKET ANALYSIS	84
FIGURE 31	ADJACENT MARKETS TO WEARABLE INJECTORS MARKET	84
6	WEARABLE INJECTORS MARKET, BY TYPE	85
6.1	INTRODUCTION	86
TABLE 16	WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	86
6.2	ON-BODY WEARABLE INJECTORS	86
6.2.1	ON-BODY WEARABLE INJECTORS TO COMMAND LARGEST MARKET SHARE DURING FORECAST PERIOD	86
TABLE 17	WEARABLE INJECTORS MARKET FOR ON-BODY WEARABLE INJECTORS, BY COUNTRY, 2021-2029 (USD MILLION)	87
6.3	OFF-BODY WEARABLE INJECTORS	87
6.3.1	EASY AND CONTINUOUS DRUG DELIVERY AT REGULAR INTERVALS TO DRIVE MARKET	87
TABLE 18	WEARABLE INJECTORS MARKET FOR OFF-BODY WEARABLE INJECTORS, BY COUNTRY, 2021-2029 (USD MILLION)	88
6.4	DEVICE-ONLY WEARABLE INJECTORS	89
6.4.1	EASE OF ADMINISTRATION TO SUPPORT MARKET GROWTH	89
TABLE 19	WEARABLE INJECTORS MARKET FOR DEVICE-ONLY WEARABLE INJECTORS, BY COUNTRY, 2021-2029 (USD MILLION)	89
7	WEARABLE INJECTORS MARKET, BY TECHNOLOGY	90
7.1	INTRODUCTION	91
TABLE 20	WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	91
7.2	SPRING-BASED TECHNOLOGY	91
7.2.1	MINIMAL DISCOMFORT AND ANXIETY FOR PATIENTS WITH NEEDLE PHOBIA TO PROPEL MARKET	91
TABLE 21	WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)	92
7.3	MOTOR-DRIVEN TECHNOLOGY	92
7.3.1	TECHNOLOGICAL ADVANCEMENTS AND IMPROVED SAFETY TO AID MARKET GROWTH	92

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 22	WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)	93
7.4	ROTARY PUMP TECHNOLOGY	93
7.4.1	HIGHER PRECISION AND BETTER CONTROL OVER VISCOUS MEDICINES TO SUPPORT MARKET GROWTH	93
TABLE 23	WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)	94
7.5	EXPANDING BATTERY TECHNOLOGY	95
7.5.1	REDUCED PRODUCTION COST AND EASE OF USAGE TO DRIVE MARKET	95
TABLE 24	WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)	95
7.6	OTHER TECHNOLOGIES	96
TABLE 25	WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2029 (USD MILLION)	96
8	WEARABLE INJECTORS MARKET, BY INDICATION	97
8.1	INTRODUCTION	98
TABLE 26	WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	98
8.2	DIABETES	98
8.2.1	HIGH PREVALENCE OF DIABETES TO DRIVE MARKET	98
TABLE 27	INSULIN DEVICES AVAILABLE FOR DIABETIC PATIENTS	99
TABLE 28	WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2021-2029 (USD MILLION)	100
8.3	IMMUNO-ONCOLOGY	100
8.3.1	INCREASING NUMBER OF CANCER CASES TO BOOST MARKET GROWTH	100
TABLE 29	WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2021-2029 (USD MILLION)	101
8.4	CARDIOVASCULAR DISEASES	101
8.4.1	RIISING CASES OF HEART FAILURE AMONG ADULTS TO PROPEL MARKET GROWTH	101
TABLE 30	WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)	102
8.5	CHRONIC PAINS	102
8.5.1	INCREASING RESEARCH IN PAIN MANAGEMENT TO SUPPORT MARKET GROWTH	102
TABLE 31	WEARABLE INJECTORS MARKET FOR CHRONIC PAINS, BY COUNTRY, 2021-2029 (USD MILLION)	103
8.6	OTHER DISEASES	103
TABLE 32	WEARABLE INJECTORS MARKET FOR OTHER DISEASES, BY COUNTRY, 2021-2029 (USD MILLION)	104
9	WEARABLE INJECTORS MARKET, BY END USER	105
9.1	INTRODUCTION	106
TABLE 33	WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	106
9.2	HOSPITALS AND CLINICS	106
9.2.1	HOSPITALS AND CLINICS TO COMMAND LARGEST END-USER SEGMENT OF END USER DURING STUDY PERIOD	106
TABLE 34	WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2029 (USD MILLION)	107
9.3	HOME CARE SETTINGS	107
9.3.1	RIISING PREFERENCE FOR SELF-ADMINISTRATION OF MEDICINE TO DRIVE MARKET	107
TABLE 35	WEARABLE INJECTORS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021-2029 (USD MILLION)	108
9.4	OTHER END USERS	109
TABLE 36	WEARABLE INJECTORS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2029 (USD MILLION)	109
10	WEARABLE INJECTORS MARKET, BY REGION	110
10.1	INTRODUCTION	111
FIGURE 32	WEARABLE INJECTORS MARKET: REGIONAL SNAPSHOT	111
TABLE 37	WEARABLE INJECTORS MARKET, BY REGION, 2021-2029 (USD MILLION)	112
10.2	NORTH AMERICA	112
FIGURE 33	NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT	113
TABLE 38	NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	114
TABLE 39	NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	114
TABLE 40	NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	115

TABLE 41	NORTH AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	115
TABLE 42	NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	116
10.2.1	NORTH AMERICA: RECESSION IMPACT	116
10.2.2	US	116
10.2.2.1	Favorable reimbursement scenario and high prevalence of chronic diseases to drive market	116
TABLE 43	US: KEY MACROINDICATORS	117
TABLE 44	US: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	117
TABLE 45	US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	118
TABLE 46	US: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	118
TABLE 47	US: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	119
10.2.3	CANADA	119
10.2.3.1	Growing biologics market to propel market growth	119
TABLE 48	CANADA: KEY MACROINDICATORS	120
TABLE 49	CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	120
TABLE 50	CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	121
TABLE 51	CANADA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	121
TABLE 52	CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	122
10.3	EUROPE	122
TABLE 53	EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	122
TABLE 54	EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	123
TABLE 55	EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	123
TABLE 56	EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	124
TABLE 57	EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	124
10.3.1	EUROPE: RECESSION IMPACT	124
10.3.2	GERMANY	125
10.3.2.1	Favorable government policies for drug development and approval to aid market growth	125
TABLE 58	GERMANY: KEY MACROINDICATORS	125
TABLE 59	GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	125
TABLE 60	GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	126
TABLE 61	GERMANY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	126
TABLE 62	GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	127
10.3.3	FRANCE	127
10.3.3.1	Increased prevalence of diabetes and favorable insurance coverage by SHI to drive market	127
TABLE 63	FRANCE: KEY MACROINDICATORS	127
TABLE 64	FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	128
TABLE 65	FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	128
TABLE 66	FRANCE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	129
TABLE 67	FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	129
10.3.4	UK	129
10.3.4.1	Rising focus on development and promotion of biosimilars and biologics to propel market growth	129
TABLE 68	UK: KEY MACROINDICATORS	130
TABLE 69	UK: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	130
TABLE 70	UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	131
TABLE 71	UK: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	131
TABLE 72	UK: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	132
10.3.5	ITALY	132
10.3.5.1	Rising prevalence of diabetes to support market growth	132

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 73 ITALY: MACROECONOMIC INDICATORS 132

TABLE 74 ITALY: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 133

TABLE 75 ITALY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 133

TABLE 76 ITALY: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 134

TABLE 77 ITALY: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 134

10.3.6 SPAIN 134

10.3.6.1 Increased preference for less painful drug delivery systems among geriatric population to drive market 134

TABLE 78 SPAIN: MACROECONOMIC INDICATORS 135

TABLE 79 SPAIN: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 135

TABLE 80 SPAIN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 136

TABLE 81 SPAIN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 136

TABLE 82 SPAIN: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 137

10.3.7 REST OF EUROPE 137

TABLE 83 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 137

TABLE 84 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 138

TABLE 85 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 138

TABLE 86 REST OF EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 139

10.4 ASIA PACIFIC 139

FIGURE 34 ASIA PACIFIC: WEARABLE INJECTORS MARKET SNAPSHOT 140

TABLE 87 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021-2029 (USD MILLION) 141

TABLE 88 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 141

TABLE 89 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 142

TABLE 90 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 142

TABLE 91 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 143

10.4.1 ASIA PACIFIC: RECESSION IMPACT 143

10.4.2 JAPAN 143

10.4.2.1 Increasing number of patients suffering from diabetes, CVD, and chronic conditions to drive market 143

TABLE 92 JAPAN: MACROECONOMIC INDICATORS 144

TABLE 93 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 144

TABLE 94 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 145

TABLE 95 JAPAN: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 145

TABLE 96 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 146

10.4.3 CHINA 146

10.4.3.1 Favorable government initiatives and improved access to advanced healthcare to drive market 146

TABLE 97 CHINA: MACROECONOMIC INDICATORS 146

TABLE 98 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 147

TABLE 99 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 147

TABLE 100 CHINA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 148

TABLE 101 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 148

10.4.4 INDIA 148

10.4.4.1 Growing burden of diabetes and increasing need to reduce healthcare costs to propel market 148

TABLE 102 INDIA: MACROECONOMIC INDICATORS 149

TABLE 103 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION) 149

TABLE 104 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION) 150

TABLE 105 INDIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION) 150

TABLE 106 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION) 151

10.4.5 AUSTRALIA 151

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.4.5.1	Favorable government initiatives for diabetes treatment to drive market	151
TABLE 107	AUSTRALIA: MACROECONOMIC INDICATORS	151
TABLE 108	AUSTRALIA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	152
TABLE 109	AUSTRALIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	152
TABLE 110	AUSTRALIA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	153
TABLE 111	AUSTRALIA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	153
10.4.6	SOUTH KOREA	154
10.4.6.1	Increased number of government initiatives for diabetes management to drive market	154
TABLE 112	SOUTH KOREA: KEY MACROINDICATORS	154
TABLE 113	SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	154
TABLE 114	SOUTH KOREA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	155
TABLE 115	SOUTH KOREA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	155
TABLE 116	SOUTH KOREA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	156
10.4.7	REST OF ASIA PACIFIC	156
TABLE 117	REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	156
TABLE 118	REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	157
TABLE 119	REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	157
TABLE 120	REST OF ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	158
10.5	LATIN AMERICA	158
TABLE 121	LATIN AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2021-2029 (USD MILLION)	158
TABLE 122	LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	159
TABLE 123	LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	159
TABLE 124	LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	160
TABLE 125	LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	160
10.5.1	LATIN AMERICA: RECESSION IMPACT	161
10.5.2	BRAZIL	161
10.5.2.1	Increasing number of government initiatives for improving healthcare sector to boost market	161
TABLE 126	BRAZIL: MACROECONOMIC INDICATORS	161
TABLE 127	BRAZIL: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	162
TABLE 128	BRAZIL: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	162
TABLE 129	BRAZIL: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	163
TABLE 130	BRAZIL: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	163
10.5.3	MEXICO	164
10.5.3.1	Increasing prevalence of diabetes and obesity-related diseases to boost market growth	164
TABLE 131	MEXICO: KEY MACROINDICATORS	164
TABLE 132	MEXICO: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	164
TABLE 133	MEXICO: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	165
TABLE 134	MEXICO: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	165
TABLE 135	MEXICO: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	166
10.5.4	REST OF LATIN AMERICA	166
TABLE 136	REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	166
TABLE 137	REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	167
TABLE 138	REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	167
TABLE 139	REST OF LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	168
10.6	MIDDLE EAST & AFRICA	168
TABLE 140	MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY REGION, 2021-2029 (USD MILLION)	169
TABLE 141	MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	169

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 142	MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	170
TABLE 143	MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	170
TABLE 144	MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	171
10.6.1	MIDDLE EAST & AFRICA: RECESSION IMPACT	171
10.6.2	GCC COUNTRIES	171
10.6.2.1	Growing incidence of chronic diseases to propel market	171
TABLE 145	GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	172
TABLE 146	GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	172
TABLE 147	GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	173
TABLE 148	GCC COUNTRIES: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	173
10.6.3	REST OF MIDDLE EAST & AFRICA	173
TABLE 149	REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2021-2029 (USD MILLION)	174
TABLE 150	REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021-2029 (USD MILLION)	174
TABLE 151	REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY INDICATION, 2021-2029 (USD MILLION)	175
TABLE 152	REST OF MIDDLE EAST & AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2021-2029 (USD MILLION)	175
11	COMPETITIVE LANDSCAPE	176
11.1	INTRODUCTION	176
11.2	KEY STRENGTHS/RIGHT TO WIN	176
FIGURE 35	STRATEGIES ADOPTED BY KEY PLAYERS IN WEARABLE INJECTORS MARKET, 2020-2024	177
11.3	REVENUE SHARE ANALYSIS	177
FIGURE 36	REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2018-2022	177
11.4	MARKET SHARE ANALYSIS	178
FIGURE 37	MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022	178
11.5	MANUFACTURERS OF WEARABLE DEVICES	179
TABLE 153	LIST OF KEY MANUFACTURERS OF WEARABLE DEVICES	179
11.6	COMPANY EVALUATION MATRIX	179
11.6.1	STARS	179
11.6.2	EMERGING LEADERS	179
11.6.3	PERVASIVE PLAYERS	180
11.6.4	PARTICIPANTS	180
FIGURE 38	COMPANY EVALUATION MATRIX, 2022	180
11.6.5	COMPANY FOOTPRINT	181
TABLE 154	WEARABLE INJECTORS MARKET: OVERALL FOOTPRINT	181
TABLE 155	WEARABLE INJECTORS MARKET: PRODUCT FOOTPRINT	182
TABLE 156	WEARABLE INJECTORS MARKET: REGIONAL FOOTPRINT	183
11.7	START-UP/SME EVALUATION MATRIX	184
11.7.1	PROGRESSIVE COMPANIES	184
11.7.2	RESPONSIVE COMPANIES	184
11.7.3	DYNAMIC COMPANIES	184
11.7.4	STARTING BLOCKS	184
FIGURE 39	START-UP/SME EVALUATION MATRIX, 2022	185
11.7.5	COMPETITIVE BENCHMARKING	185
TABLE 157	DETAILED LIST OF KEY START-UPS/SMES	185
11.8	R&D EXPENDITURE	186
FIGURE 40	R&D EXPENDITURE OF KEY PLAYERS, 2021 VS. 2022	186
11.9	BRAND/PRODUCT COMPARISON	186
TABLE 158	BRAND/PRODUCT COMPARISON OF KEY PLAYERS	186

11.9.1	AMGEN INC.	188
11.9.2	MEDTRONIC	188
11.9.3	INSULET CORPORATION	188
11.9.4	TANDEM DIABETES CARE, INC.	188
11.9.5	UNITED THERAPEUTICS	188
11.9.6	ABBVIE INC.	188
11.9.7	GERRESHEIMER AG	188
11.10	INVESTMENT AND FUNDING SCENARIO	189
FIGURE 41	FUNDING IN WEARABLE INJECTORS MARKET SOARED IN 2022	189
11.10.1	FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION	190
TABLE 159	FUNDING IN WEARABLE INJECTORS MARKET, BY INDICATION	190
FIGURE 42	MOST VALUED WEARABLE INJECTORS FIRMS IN 2022 (USD BILLION)	190
11.11	COMPANY FINANCIAL METRICS	190
FIGURE 43	FINANCIAL METRICS OF KEY COMPANIES, 2022	190
11.12	COMPETITIVE SCENARIO	191
11.12.1	PRODUCT LAUNCHES & APPROVALS	191
TABLE 160	WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020-2024	191
11.12.2	DEALS	191
TABLE 161	WEARABLE INJECTORS MARKET: DEALS, 2020-2024	191
11.12.3	OTHER DEVELOPMENTS	192
TABLE 162	WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS, 2020-2024	192
12	COMPANY PROFILES	193
12.1	KEY PLAYERS	193
(Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and Competitive threats)*		
12.1.1	AMGEN INC.	193
TABLE 163	AMGEN INC.: COMPANY OVERVIEW	193
FIGURE 44	AMGEN INC.: COMPANY SNAPSHOT (2022)	194
TABLE 164	AMGEN INC.: DEALS, 2020-2024	195
TABLE 165	AMGEN INC.: OTHER DEVELOPMENTS, 2020-2024	195
12.1.2	MEDTRONIC	197
TABLE 166	MEDTRONIC: COMPANY OVERVIEW	197
FIGURE 45	MEDTRONIC: COMPANY SNAPSHOT (2022)	198
TABLE 167	MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, 2020-2024	199
TABLE 168	MEDTRONIC: DEALS, 2020-2024	199
12.1.3	INSULET CORPORATION	201
TABLE 169	INSULET CORPORATION: COMPANY OVERVIEW	201
FIGURE 46	INSULET CORPORATION: COMPANY SNAPSHOT (2022)	202
TABLE 170	INSULET CORPORATION: PRODUCT LAUNCHES & APPROVALS, 2020-2024	203
TABLE 171	INSULET CORPORATION: DEALS, 2020-2024	203
12.1.4	TANDEM DIABETES CARE, INC.	205
TABLE 172	TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW	205
FIGURE 47	TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022)	205
TABLE 173	TANDEM DIABETES CARE, INC.: DEALS, 2020-2024	206
12.1.5	UNITED THERAPEUTICS CORPORATION	207
TABLE 174	UNITED THERAPEUTICS CORPORATION: COMPANY OVERVIEW	207
FIGURE 48	UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2022)	208

TABLE 175	UNITED THERAPEUTICS CORPORATION: DEALS, 2020-2024	209
12.1.6	ABBVIE INC.	210
TABLE 176	ABBVIE INC.: COMPANY OVERVIEW	210
FIGURE 49	ABBVIE INC.: COMPANY SNAPSHOT (2022)	211
TABLE 177	ABBVIE INC.: PRODUCT LAUNCHES & APPROVALS, 2020-2024	211
12.1.7	GERRESHEIMER AG	212
TABLE 178	GERRESHEIMER AG: COMPANY OVERVIEW	212
FIGURE 50	GERRESHEIMER AG: COMPANY SNAPSHOT (2022)	213
TABLE 179	GERRESHEIMER AG: PRODUCT LAUNCHES & APPROVALS, 2020-2024	214
TABLE 180	GERRESHEIMER AG: DEALS, 2020-2024	214
12.1.8	BECTON, DICKISON AND COMPANY	215
TABLE 181	BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW	215
FIGURE 51	BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)	216
TABLE 182	BECTON, DICKINSON AND COMPANY: DEALS, 2020-2024	217
TABLE 183	BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, 2020-2024	217
12.1.9	WEST PHARMACEUTICAL SERVICES, INC.	218
TABLE 184	WEST PHARMACEUTICAL SERVICES, INC.: COMPANY OVERVIEW	218
FIGURE 52	WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2022)	219
12.1.10	YPSOMED HOLDING AG	220
TABLE 185	YPSOMED HOLDING AG: COMPANY OVERVIEW	220
FIGURE 53	YPSOMED HOLDING AG: COMPANY SNAPSHOT (2022)	221
TABLE 186	YPSOMED HOLDING AG: PRODUCT LAUNCHES & APPROVALS, 2020-2024	222
TABLE 187	YPSOMED HOLDING AG: DEALS, 2020-2024	222
TABLE 188	YPSOMED HOLDING AG: OTHER DEVELOPMENTS, 2020-2024	222
12.1.11	ENABLE INJECTIONS	223
TABLE 189	ENABLE INJECTIONS: COMPANY OVERVIEW	223
TABLE 190	ENABLE INJECTIONS: PRODUCT LAUNCHES & APPROVALS, 2020-2024	223
TABLE 191	ENABLE INJECTIONS: DEALS, 2020-2024	224
TABLE 192	ENABLE INJECTIONS: OTHER DEVELOPMENTS, 2020-2024	224
12.1.12	SUBCUJECT APS	225
TABLE 193	SUBCUJECT APS: COMPANY OVERVIEW	225
12.1.13	CEQUR SIMPLICITY	226
TABLE 194	CEQUR SIMPLICITY: COMPANY OVERVIEW	226
TABLE 195	CEQUR SIMPLICITY: OTHER DEVELOPMENTS, 2020-2024	226
12.1.14	MANNKIND CORPORATION	227
TABLE 196	MANNKIND CORPORATION: COMPANY OVERVIEW	227
FIGURE 54	MANNKIND CORPORATION: COMPANY SNAPSHOT (2022)	227
TABLE 197	MANNKIND CORPORATION: DEALS, 2020-2024	228
TABLE 198	MANNKIND CORPORATION: OTHER DEVELOPMENTS, 2020-2024	228
12.1.15	SONCEBOZ	229
TABLE 199	SONCEBOZ: COMPANY OVERVIEW	229
12.1.16	CC BIO	230
TABLE 200	CC BIO: COMPANY OVERVIEW	230
TABLE 201	CC BIO: DEALS, 2020-2024	230
12.1.17	ELCAM DRUG DELIVERY DEVICES	231
TABLE 202	ELCAM DRUG DELIVERY DEVICES: COMPANY OVERVIEW	231
TABLE 203	ELCAM DRUG DELIVERY DEVICES: DEALS, 2020-2024	231

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.1.18 STEVANATO GROUP 232

TABLE 204 STEVANATO GROUP: COMPANY OVERVIEW 232

12.1.19 DEBIOTECH SA 233

TABLE 205 DEBIOTECH SA: COMPANY OVERVIEW 233

12.2 OTHER PLAYERS 234

12.2.1 BEXSON BIOMEDICAL 234

12.2.2 NEMERA 234

12.2.3 LTS LOHMANN THERAPIE-SYSTEME AG 235

12.2.4 KYMANOX CORPORATION 235

12.2.5 NOVO ENGINEERING 236

12.2.6 EOFLOW CO., LTD. 236

*Details on Business overview, Products/Solutions/Services offered, Recent developments, Deals, MnM view, Key strengths/Right to win, Strategic choices, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.

13 APPENDIX 237

13.1 DISCUSSION GUIDE 237

13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 241

13.3 CUSTOMIZATION OPTIONS 243

13.4 RELATED REPORTS 243

13.5 AUTHOR DETAILS 244

Wearable Injectors Market by Type(On-body, Off-body), Technology (Spring, Motor Drive, Expanding Battery, Rotary Pump), Indications (Diabetes, Immuno- Oncology, Cardiovascular, Chronic Pain), End Users (Hospital & Clinic, Homecare) - Global Forecast to 2029

Market Report | 2024-02-09 | 237 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-20
		Signature	<div></div>